Online inquiry

IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13616MR)

This product GTTS-WQ13616MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13616MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10904MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ15369MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ9785MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ3131MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ2397MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ15861MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ15725MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ3763MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1834942
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW